Multiple Sclerosis - New Rebif® Formulation Submitted In USA And Europe
Sun, 09 Apr 2006 11:00 PM EST
... Serono (virt-x:SEO and NYSE: SRA) announced today the submission of a supplemental Biologics Licence Application (sBLA) to the US Food and Drug Administration (FDA) and of a variation to the current Marketing Authorization to the European Medicines Agency (EMEA) for a new formulation of Rebif® (interferon beta-1a) as a treatment of multiple sclerosis (MS)... click link for more info. ...
Related Topics
- Multiple Sclerosis/ms
- Multiple Sclerosis
- Tuberous Sclerosis
- Multiple Myeloma
- Myeloma, Multiple
- Myeloma
- Lichen Sclerosis
- Multiple Chemical Sensitivity
- Europe, Western
- Interferon Beta-1a Injection (Rebif
- Twins, Triplets, Multiple Births
- Eastern Europe and Northern Asia
- Interferon Beta-1a Injection (Avonex
- Multiple System Atrophy
- Recessive multiple epiphyseal dysplasia
- Naltrexone
- Hypothermia
- Aspartame
- Cerebral Atrophy
- Juvenile primary lateral sclerosis

Not Signed In -


